Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in January 2017 at the end of the period of market exclusivity.
On 5 December 2001 orphan designation (EU/3/01/071) was granted by the European Commission to Biocodex, France, for stiripentol for the treatment of severe myoclonic epilepsy in infancy.
Stiripentol has been authorised in the EU as Diacomit since 4 January 2007.
|Disease / condition||
Treatment of severe myoclonic epilepsy in infancy
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.